AstraZeneca

Corridor footprint

Anglo-Swedish biopharmaceutical group formed in 1999 by the merger of Sweden’s Astra AB (founded 1913 in Södertälje) and the UK’s Zeneca; it remains listed on Nasdaq Stockholm alongside London. Its Portuguese subsidiary is AstraZeneca – Produtos Farmacêuticos, Lda (NIF 502942240; CAE 46460, wholesale of pharmaceutical products; share capital €1.5 million), which the Portuguese business register lists under its former name Astra Portuguesa – Produtos Farmacêuticos, Lda. On 1 April 2026 it opened a new Portuguese head office in Parque das Nações (Av. Dom João II, 13, 1990-077 Lisboa).

According to AstraZeneca Portugal, the opening of the Parque das Nações head office on 1 April 2026 was attended by Health Minister Ana Paula Martins and Finance Minister Joaquim Miranda Sarmento, with a panel that included AstraZeneca Portugal president Nathalie Cardinal von Widdern, Ruud Dobber (executive vice-president of the group’s BioPharmaceuticals business unit) and Lisbon mayor Carlos Moedas. The company says its investment in Portugal runs both through the local subsidiary and through a global services hub, launched in 2024, that serves AstraZeneca worldwide from Lisbon. Before the move the subsidiary was based in Queluz de Baixo (Oeiras), where the separate Fundação AstraZeneca (NIF 505284898) is also registered.

Why this matters

AstraZeneca sits inside the Portugal ↔ Scandinavia business corridor that NorthSouth HQ tracks every day. Its Portuguese company began life as the local arm of Sweden’s Astra, and the group now runs both its Portuguese subsidiary and a global services hub from Lisbon.